{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:31:28Z","timestamp":1792859488392,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,7,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The interleukin-6\/Janus kinase (JAK)\/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance. We hypothesized that adding the JAK1\/2 inhibitor ruxolitinib to standard chemotherapy would be tolerable and improve progression-free survival (PFS) in patients with ovarian cancer in the upfront setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      Patients with ovarian\/fallopian tube\/primary peritoneal carcinoma recommended for neoadjuvant chemotherapy were eligible. In phase I, treatment was initiated with dose-dense paclitaxel (P) 70 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      once daily on days 1, 8, and 15; carboplatin AUC 5 intravenously day 1; and ruxolitinib 15 mg orally (PO) twice a day, every 21 days (dose level 1). Interval debulking surgery (IDS) was required after cycle 3. Patients then received three additional cycles of chemotherapy\/ruxolitinib, followed by maintenance ruxolitinib. In the randomized phase II, patients were randomly assigned to paclitaxel\/carboplatin with or without ruxolitinib at 15 mg PO twice a day for three cycles, IDS, followed by another three cycles of chemotherapy\/ruxolitinib, without further maintenance ruxolitinib. The primary phase II end point was PFS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Seventeen patients were enrolled in phase I. The maximum tolerated dose and recommended phase II dose were established to be dose level 1. One hundred thirty patients were enrolled in phase II with a median follow-up of 24 months. The regimen was well tolerated, with a trend toward higher grade 3 to 4 anemia (64% v 27%), grade 3 to 4 neutropenia (53% v 37%), and thromboembolic events (12.6% v 2.4%) in the experimental arm. In the randomized phase II, the median PFS in the reference arm was 11.6 versus 14.6 in the experimental, hazard ratio (HR) for PFS was 0.702 (log-rank P = .059). The overall survival HR was 0.785 ( P = .24).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Ruxolitinib 15 mg PO twice a day was well tolerated with acceptable toxicity in combination with paclitaxel\/carboplatin chemotherapy. The primary end point of prolongation of PFS was achieved in the experimental arm, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.23.02076","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:59:18Z","timestamp":1716393558000},"page":"2537-2545","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":28,"title":["Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct02713386","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-2444","authenticated-orcid":false,"given":"Charles N.","family":"Landen","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5665-9790","authenticated-orcid":false,"given":"Ronald J.","family":"Buckanovich","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center and Magee-Womens Research Institute and Foundation, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-2179","authenticated-orcid":false,"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[{"name":"Clinical Trials Development Division, NRG Oncology Statistical and Data Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-4309","authenticated-orcid":false,"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-6663","authenticated-orcid":false,"given":"Paul A.","family":"DiSilvestro","sequence":"additional","affiliation":[{"name":"Women & Infants Program in Women's Oncology, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8461-4568","authenticated-orcid":false,"given":"Cara A.","family":"Mathews","sequence":"additional","affiliation":[{"name":"Women & Infants Program in Women's Oncology, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, Washington University, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia L.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Mercy Clinic Women's Oncology\u2014Whiteside, Springfield, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Bishop","sequence":"additional","affiliation":[{"name":"Froedtert & Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Gill","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology, SJC Oncology Services\u2014Georgia, LLC, Savannah, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-6520","authenticated-orcid":false,"given":"Mary E.","family":"Gordinier","sequence":"additional","affiliation":[{"name":"Norton Children's Hospital, Louisville, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA"},{"name":"Mersana Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-3972","authenticated-orcid":false,"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4255-7814","authenticated-orcid":false,"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kaiser-Permanente Northern California, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3175"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2188"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-317"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0607"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0523-6"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204990"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0800"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3145"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01225-7"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.136"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2006.00441.x"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.02.008"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2007.08.014"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0563"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0926"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.4578"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.23.02076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T18:02:21Z","timestamp":1721239341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.02076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":21,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,7,20]]}},"alternative-id":["10.1200\/JCO.23.02076"],"URL":"https:\/\/doi.org\/10.1200\/jco.23.02076","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"assertion":[{"value":"2023-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}